Remdesivir for severe COVID-19 Patients | Arriba Trends

Remdesivir for severe COVID-19 Patients


In an effort to use the substitute vaccine to cure the severely ill Covid-19 patients until the specific vaccine is not discovered, Remdesivir has successfully impressed the Gilead Sciences. In a recent report the organisation stated that the antiviral drug Remdesivir has reduced the death rate of severely ill Covid-19 patients by up-to 62% when compared to general treatment given. Along with this being the only drug licensed by the US and the European Union for the treatment of seriously ill patients now the Australian authority has also given its approval to the drug.

Read More at The Weather Channel

error: Content is protected !!